While the life science industry began piloting decentralized clinical trials (DCTs) more than 15 years ago, the COVID 19 pandemic led to tremendous growth, primarily out of necessity. As the world shut down, DCTs became the only viable option for conducting research studies. Although annual DCT growth is expected to be at 6.6% through 2030, there has been a natural slackening to the torrid pace of growth seen during the pandemic.
Sluggish adoption is a key hurdle the industry is facing. Many sites and sponsors lack the funding to move forward with DCTs as well as cover training and new technology integration. Other challenges include misaligned workflows, inflated expectations, and high dropout rates. Although there can be stiff headwinds, industry leaders are confident that DCTs will ultimately lead to successful clinical trials for all patients in need.
As workflows mature and the industry implements increased use of new technology such as AI and EHRs, professionals remain confident that we will see strong growth in DCTs while keeping patients at the center of their work.
At Greenlight, we recognize that EHRs are a critical component in treating patients now and in the future. Keeping patients at the center of our work is critical to our mission and we strive to support this in all facets of healthcare. As the industry continues to evolve and embrace changes, we look forward to the benefits it will bring to both the patients and the providers.
Read the full article here: Decentralized Clinical Trials: Bust or Breakthrough? (appliedclinicaltrialsonline.com)
